| scholarly article | Q13442814 |
| P50 | author | Peter Selby | Q46220287 |
| Alan Melcher | Q46221036 | ||
| P2093 | author name string | Debabrata Mukhopadhyay | |
| Gerard Nuovo | |||
| Kevin Harrington | |||
| Jill Thompson | |||
| Richard Vile | |||
| Elizabeth Ilett | |||
| Hardev Pandha | |||
| John Chester | |||
| Jose Pulido | |||
| Timothy Kottke | |||
| Matt Coffey | |||
| Rosa Diaz | |||
| P2860 | cites work | Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells | Q21245717 |
| Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers | Q24611483 | ||
| Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors | Q24614856 | ||
| Intelligent design: combination therapy with oncolytic viruses | Q24628227 | ||
| Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics | Q27690634 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents | Q30438696 | ||
| Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice | Q33815701 | ||
| A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer | Q34151736 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| Reovirus therapy of tumors with activated Ras pathway | Q34479740 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial | Q34759406 | ||
| VEGF-targeted therapy: mechanisms of anti-tumour activity. | Q34791610 | ||
| Directing systemic oncolytic viral delivery to tumors via carrier cells | Q35029126 | ||
| Vascular targeting agents as cancer therapeutics | Q35647684 | ||
| Recent progress in the battle between oncolytic viruses and tumours | Q36315580 | ||
| Vascular endothelial growth factor signaling pathways: therapeutic perspective | Q36584934 | ||
| Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer | Q36723147 | ||
| Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded | Q37191007 | ||
| Tumor infection by oncolytic reovirus primes adaptive antitumor immunity | Q37239555 | ||
| Diplomatic immunity: turning a foe into an ally. | Q37377700 | ||
| The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon | Q37561072 | ||
| Cell carriers for oncolytic viruses: Fed Ex for cancer therapy | Q37582184 | ||
| REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer | Q37602536 | ||
| Microtubules and resistance to tubulin-binding agents | Q37690565 | ||
| In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets | Q37781132 | ||
| Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor | Q39639933 | ||
| Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus | Q39802923 | ||
| Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication | Q39840716 | ||
| A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer | Q40405703 | ||
| Murine endothelial cell lines as models of tumor endothelial cells | Q40574091 | ||
| Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter | Q40850724 | ||
| Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. | Q41235043 | ||
| Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus | Q42063211 | ||
| Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion | Q42809739 | ||
| Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. | Q43592482 | ||
| Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways | Q43606331 | ||
| Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively | Q43660549 | ||
| Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia | Q45063954 | ||
| Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. | Q45608600 | ||
| Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin | Q46482933 | ||
| Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications | Q48136888 | ||
| A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. | Q55467147 | ||
| Systemic reovirus therapy of metastatic cancer in immune-competent mice | Q78835027 | ||
| Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy | Q80162686 | ||
| Reovirus therapy in cancer: has the orphan virus found a home? | Q82623931 | ||
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma | Q84834335 | ||
| P433 | issue | 10 | |
| P921 | main subject | chemotherapy | Q974135 |
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 1802-1812 | |
| P577 | publication date | 2011-07-26 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy | |
| P478 | volume | 19 |
| Q39319601 | An intravenous stimulus package for oncolytic virotherapy |
| Q38243811 | Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines. |
| Q26863779 | Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances |
| Q57161784 | Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity |
| Q35596563 | Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus |
| Q37477557 | Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence |
| Q37459636 | Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms |
| Q35545752 | In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells |
| Q38756832 | Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions |
| Q35534823 | Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents |
| Q38842126 | Oncolytic virotherapy for urological cancers |
| Q91749359 | Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition |
| Q47781149 | Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence |
| Q27021951 | Trial Watch:: Oncolytic viruses for cancer therapy |
| Q37028023 | Trial watch: Oncolytic viruses for cancer therapy |
Search more.